CLYM

+ Watchlist + Portfolio

Climb Bio, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $17.34
52-Week Range: $1.54 – $18.14
Market Cap: $977.57M
P/E (TTM): —
EPS (TTM): -0.82
Dividend Yield: —

Advanced Metrics

Price/Book: 4.08
PEG Ratio: —
Return on Equity: -27.10%
Return on Assets: -18.45%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 31.45
Debt/Equity: 0.01
Total Debt: $1.31M
Free Cash Flow: $-33.99M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $795.18M

CLYM Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$26.21M	$15.41M	$14.34M	$46.71M
Selling, General & Admin	$18.92M	$24.86M	$16.02M	$21.17M
Operating Expenses	$45.13M	$40.27M	$30.36M	$67.88M
Operating Income	-$45.13M	-$40.27M	-$30.36M	-$67.88M
EBITDA	-$45.13M	-$40.27M	-$30.36M	-$67.79M
Pretax Income	-$45.24M	-$35.12M	-$73.90M	-$59.85M
Net Income	-$45.24M	-$35.12M	-$73.90M	-$59.85M
Diluted EPS	-1.72	-1.30	-1.53	-0.88
Diluted Shares	26.31M	26.99M	48.30M	47.77M

CLYM Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.59M	$93.11M	$87.23M	$35.69M
Receivables	$6.49M	$2.46M	$1.12M	—
Current Assets	$134.39M	$110.25M	$154.87M	$105.85M
Total Assets	$134.99M	$110.47M	$217.19M	$167.74M
Current Liabilities	$6.10M	$2.83M	$4.93M	$6.98M
Total Debt	$480.00K	$349.00K	$532.00K	$541.00K
Total Liabilities	$6.28M	$2.87M	$5.31M	$7.27M
Retained Earnings	-$120.86M	-$155.98M	-$229.88M	-$289.73M
Shareholders' Equity	$128.72M	$107.60M	$211.88M	$160.47M
Working Capital	$128.30M	$107.42M	$149.94M	$98.86M

CLYM Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$37.37M	-$20.60M	-$15.56M	-$54.36M
Capital Expenditure	—	—	—	-$186.00K
Free Cash Flow	-$37.37M	-$20.60M	-$15.56M	-$54.54M
Depreciation & Amortisation	—	—	$0.00	$97.00K
Stock-Based Compensation	$6.99M	$12.81M	$5.56M	$8.05M
Investing Cash Flow	$34.44M	$68.98M	-$121.09M	$2.83M
Financing Cash Flow	$0.00	$841.00K	$130.73M	-$21.00K
Net Change in Cash	-$2.93M	$49.22M	-$5.92M	-$51.54M

CLYM Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.33M	$6.58M	$9.07M	$13.74M	$9.37M
Selling, General & Admin	$5.69M	$4.10M	$5.82M	$5.56M	$5.84M
Operating Expenses	$23.02M	$10.68M	$14.89M	$19.30M	$15.21M
Operating Income	-$23.02M	-$10.68M	-$14.89M	-$19.30M	-$15.21M
EBITDA	-$23.02M	-$10.64M	-$14.86M	-$19.27M	-$15.17M
Pretax Income	-$20.78M	-$8.67M	-$12.89M	-$17.52M	-$13.72M
Net Income	-$20.78M	-$8.67M	-$12.89M	-$17.52M	-$13.72M
Diluted EPS	-0.31	-0.13	-0.19	-0.26	-0.20
Diluted Shares	67.46M	67.59M	68.00M	47.77M	68.21M

CLYM Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$29.02M	$22.68M	$25.80M	$35.69M	$8.36M
Receivables	$1.37M	—	—	—	—
Current Assets	$100.28M	$87.38M	$90.96M	$105.85M	$113.40M
Total Assets	$200.74M	$192.39M	$182.30M	$167.74M	$152.37M
Current Liabilities	$7.04M	$6.21M	$4.95M	$6.98M	$4.07M
Total Debt	$474.00K	$639.00K	$580.00K	$541.00K	$479.00K
Total Liabilities	$7.36M	$6.62M	$5.30M	$7.27M	$4.29M
Retained Earnings	-$250.66M	-$259.32M	-$272.21M	-$289.73M	-$303.45M
Shareholders' Equity	$193.38M	$185.76M	$177.00M	$160.47M	$148.09M
Working Capital	$93.24M	$81.18M	$86.02M	$98.86M	$109.33M

CLYM Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$15.43M	-$11.15M	-$12.14M	-$15.63M	-$14.38M
Capital Expenditure	—	—	-$109.00K	—	—
Free Cash Flow	-$15.43M	-$11.22M	-$12.25M	-$15.63M	-$14.38M
Depreciation & Amortisation	$0.00	$38.00K	$29.00K	$30.00K	$38.00K
Stock-Based Compensation	$2.02M	$1.01M	$3.98M	$1.04M	$1.60M
Investing Cash Flow	-$42.75M	$4.79M	$15.26M	$25.54M	-$12.96M
Financing Cash Flow	$0.00	$0.00	$0.00	-$21.00K	$5.00K
Net Change in Cash	-$58.19M	-$6.36M	$3.12M	$9.88M	-$27.33M

Market Snapshot

About

Climb Bio, Inc. is a clinical-stage biotechnology company developing therapeutic antibodies for immune-mediated diseases. Based in King of Prussia, Pennsylvania, the company's lead program, budoprutug, is a monoclonal antibody targeting IL-17A/F designed to treat moderate to severe plaque psoriasis and potentially other inflammatory conditions. Climb Bio leverages its expertise in immunology to advance candidates addressing unmet needs in dermatology and other therapeutic areas. The company focuses on precision medicine approaches using biomarkers to identify patients most likely to benefit from its therapies.